Small Cell Glioblastoma
Small cell glioblastomas most frequently harbor alterations in TP53, PTEN, CDKN2B, CDKN2A, and EGFR .
TP53 c.217-c.1178 Missense, TP53 Mutation, TP53 Missense, CDKN2B Loss, and CDKN2A Loss are the most common alterations in small cell glioblastoma .
There is 1 clinical trial for small cell glioblastoma, of which 1 is open and 0 are completed or closed. Of the trial that contains small cell glioblastoma as an inclusion criterion, 1 is phase 2 (1 open).
Regorafenib is the most common intervention in small cell glioblastoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.